Open AccessD2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
Author(s) -
Peng Jin,
Wei Yuehua,
Zhou Fuxiang,
Dai Jing,
Zhong Yahua,
Xie Conghua,
Qin Yue'e,
Gong Jun,
Xiong Bin,
Zhou Yunfeng
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.873
Subject(s) - stage (stratigraphy) , medicine , chemoradiotherapy , adjuvant , cancer , oncology , biology , paleontology
Although adjuvant chemoradiotherapy has been an important part in the treatment of gastric cancer, whether or not adjuvant radiation can benefit patients undergoing resection with D2 lymph node dissection remains controversial. This retrospective study aimed to evaluate the role of adjuvant chemoradiotherapy on patients with D2‐resected gastric cancer. A total of 337 patients with resected gastric cancer treated at Zhongnan Hospital of Wuhan University from 2004 to 2012 were retrospectively analyzed. Eligible patients were divided into the adjuvant chemoradiotherapy group ( CRT ; n = 124) and the adjuvant chemotherapy group ( CT ; n = 213). The primary endpoints were disease‐free survival ( DFS ) and overall survival ( OS ), with toxicity as the secondary endpoint. A subgroup analysis was performed based on clinical staging. The two groups were comparable in baseline characteristic, except for the number of lymph nodes dissected. The median OS s in the CRT and CT groups were 51.0 months and 48.6 months, respectively ( P = 0.251), and the median DFS s were 40.7 months and 31.2 months, respectively ( P = 0.112). Subgroup analysis revealed that the median OS s in patients at stage III c in the CRT group and CT group were 29.0 and 23.0 months, respectively ( P = 0.049), and those of the median DFS s were 21.2 and 15.1 months, respectively ( P = 0.015). There was no significant difference in main adverse events between two groups. Collectively, adjuvant chemoradiotherapy in gastric cancer patients with D2 resection was well tolerated. For Stage IIIc patients, the addition of adjuvant chemoradiotherapy was associated with a significant benefit in both OS and DFS .